BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis

FRA:BSX • US1011371077

64.8 EUR
+0.6 (+0.93%)
Last: Feb 19, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

Taking everything into account, BSX scores 5 out of 10 in our fundamental rating. BSX was compared to 67 industry peers in the Health Care Equipment & Supplies industry. While BSX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. BSX is valued quite expensively, but it does show have an excellent growth rating. These ratings could make BSX a good candidate for growth investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • BSX had positive earnings in the past year.
  • BSX had a positive operating cash flow in the past year.
  • In the past 5 years BSX has always been profitable.
  • BSX had a positive operating cash flow in 4 of the past 5 years.
BSX.DE Yearly Net Income VS EBIT VS OCF VS FCFBSX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • BSX has a Return On Assets of 6.54%. This is in the better half of the industry: BSX outperforms 74.63% of its industry peers.
  • The Return On Equity of BSX (11.93%) is better than 71.64% of its industry peers.
  • The Return On Invested Capital of BSX (8.35%) is better than 67.16% of its industry peers.
Industry RankSector Rank
ROA 6.54%
ROE 11.93%
ROIC 8.35%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BSX.DE Yearly ROA, ROE, ROICBSX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

1.3 Margins

  • BSX has a better Profit Margin (14.42%) than 83.58% of its industry peers.
  • In the last couple of years the Profit Margin of BSX has grown nicely.
  • Looking at the Operating Margin, with a value of 19.40%, BSX belongs to the top of the industry, outperforming 80.60% of the companies in the same industry.
  • In the last couple of years the Operating Margin of BSX has grown nicely.
  • BSX has a Gross Margin of 68.57%. This is in the better half of the industry: BSX outperforms 76.12% of its industry peers.
  • BSX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 19.4%
PM (TTM) 14.42%
GM 68.57%
OM growth 3Y6.45%
OM growth 5Y16.7%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y-0.1%
GM growth 5Y1.06%
BSX.DE Yearly Profit, Operating, Gross MarginsBSX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • BSX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • There is no outstanding debt for BSX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BSX.DE Yearly Shares OutstandingBSX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B
BSX.DE Yearly Total Debt VS Total AssetsBSX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • BSX has an Altman-Z score of 4.49. This indicates that BSX is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of BSX (4.49) is better than 76.12% of its industry peers.
  • The Debt to FCF ratio of BSX is 3.03, which is a good value as it means it would take BSX, 3.03 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of BSX (3.03) is better than 71.64% of its industry peers.
  • BSX has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
  • BSX has a Debt to Equity ratio (0.48) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.03
Altman-Z 4.49
ROIC/WACC0.86
WACC9.73%
BSX.DE Yearly LT Debt VS Equity VS FCFBSX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

  • BSX has a Current Ratio of 1.51. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
  • BSX has a Current ratio of 1.51. This is comparable to the rest of the industry: BSX outperforms 44.78% of its industry peers.
  • A Quick Ratio of 0.96 indicates that BSX may have some problems paying its short term obligations.
  • BSX has a worse Quick ratio (0.96) than 62.69% of its industry peers.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 0.96
BSX.DE Yearly Current Assets VS Current LiabilitesBSX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.51%, which is quite impressive.
  • The Earnings Per Share has been growing by 26.01% on average over the past years. This is a very strong growth
  • Looking at the last year, BSX shows a quite strong growth in Revenue. The Revenue has grown by 19.88% in the last year.
  • The Revenue has been growing by 15.16% on average over the past years. This is quite good.
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%

3.2 Future

  • BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.13% yearly.
  • The Revenue is expected to grow by 10.46% on average over the next years. This is quite good.
EPS Next Y14.83%
EPS Next 2Y14.13%
EPS Next 3Y13.68%
EPS Next 5Y13.13%
Revenue Next Year11.42%
Revenue Next 2Y11.15%
Revenue Next 3Y10.54%
Revenue Next 5Y10.46%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BSX.DE Yearly Revenue VS EstimatesBSX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B 40B
BSX.DE Yearly EPS VS EstimatesBSX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 24.92, BSX is valued on the expensive side.
  • BSX's Price/Earnings is on the same level as the industry average.
  • BSX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.09.
  • A Price/Forward Earnings ratio of 21.74 indicates a rather expensive valuation of BSX.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BSX is on the same level as its industry peers.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.98, BSX is valued a bit cheaper.
Industry RankSector Rank
PE 24.92
Fwd PE 21.74
BSX.DE Price Earnings VS Forward Price EarningsBSX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BSX is valued a bit more expensive than 67.16% of the companies in the same industry.
  • BSX's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 29.54
EV/EBITDA 24.15
BSX.DE Per share dataBSX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • BSX has a very decent profitability rating, which may justify a higher PE ratio.
  • BSX's earnings are expected to grow with 13.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.68
PEG (5Y)0.96
EPS Next 2Y14.13%
EPS Next 3Y13.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BSX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BOSTON SCIENTIFIC CORP

FRA:BSX (2/19/2026, 7:00:00 PM)

64.8

+0.6 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04
Earnings (Next)04-21
Inst Owners94.07%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap96.10B
Revenue(TTM)20.07B
Net Income(TTM)2.79B
Analysts86
Price Target107.92 (66.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)-1.07%
PT rev (3m)-2.37%
EPS NQ rev (1m)-0.01%
EPS NQ rev (3m)-0.01%
EPS NY rev (1m)0.01%
EPS NY rev (3m)0.12%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)0.04%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-0.01%
Valuation
Industry RankSector Rank
PE 24.92
Fwd PE 21.74
P/S 5.84
P/FCF 29.54
P/OCF 24.42
P/B 4.83
P/tB N/A
EV/EBITDA 24.15
EPS(TTM)2.6
EY4.01%
EPS(NY)2.98
Fwd EY4.6%
FCF(TTM)2.19
FCFY3.38%
OCF(TTM)2.65
OCFY4.09%
SpS11.1
BVpS13.42
TBVpS-1.14
PEG (NY)1.68
PEG (5Y)0.96
Graham Number28.02
Profitability
Industry RankSector Rank
ROA 6.54%
ROE 11.93%
ROCE 10.04%
ROIC 8.35%
ROICexc 8.65%
ROICexgc 29.1%
OM 19.4%
PM (TTM) 14.42%
GM 68.57%
FCFM 19.76%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5Y16.7%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y-0.1%
GM growth 5Y1.06%
F-Score6
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.03
Debt/EBITDA 2.18
Cap/Depr 59.36%
Cap/Sales 4.14%
Interest Coverage 250
Cash Conversion 90.6%
Profit Quality 136.98%
Current Ratio 1.51
Quick Ratio 0.96
Altman-Z 4.49
F-Score6
WACC9.73%
ROIC/WACC0.86
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
EPS Next Y14.83%
EPS Next 2Y14.13%
EPS Next 3Y13.68%
EPS Next 5Y13.13%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%
Revenue Next Year11.42%
Revenue Next 2Y11.15%
Revenue Next 3Y10.54%
Revenue Next 5Y10.46%
EBIT growth 1Y30.66%
EBIT growth 3Y24.06%
EBIT growth 5Y34.39%
EBIT Next Year25.02%
EBIT Next 3Y15.69%
EBIT Next 5Y14.81%
FCF growth 1Y77.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.53%
OCF growth 3YN/A
OCF growth 5YN/A

BOSTON SCIENTIFIC CORP / BSX.DE FAQ

What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE.


What is the valuation status for BSX stock?

ChartMill assigns a valuation rating of 3 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Overvalued.


How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?

BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 7 / 10.


What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 24.92 and the Price/Book (PB) ratio is 4.83.


Can you provide the expected EPS growth for BSX stock?

The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 14.83% in the next year.